CliffBio
biologic

Prevnar 20

Pneumococcal 20-valent Conjugate Vaccine

Loss of exclusivityJune 2033FDA regulatory exclusivity expiry
CompanyWyeth →View the full company profile on CliffBio

Drug detail

Brand namePrevnar 20
Active ingredientPneumococcal 20-valent Conjugate Vaccine
Strength0.5 ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJune 2021
Marketing statusRx

More from Wyeth

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Prevnar 20 patent cliff — loss of exclusivity June 2033 | CliffBio